David Sallman, MD, Moffitt Cancer Center, Tampa, FL, briefly comments on a Phase I study (NCT05024552) investigating a treatment regimen of CPX-351 plus gilteritinib in relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), highlighting the potential of combination therapy to improve response rates and tolerability, but notes that this combination may not be synergistic and is unlikely to be a pivotal strategy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
